keyword
MENU ▼
Read by QxMD icon Read
search

Prostate cancer treatment

keyword
https://www.readbyqxmd.com/read/29792952/anticancer-mechanism-of-sinapic-acid-in-pc-3-and-lncap-human-prostate-cancer-cell-lines
#1
Canan Eroğlu, Ebru Avcı, Hasibe Vural, Ercan Kurar
Sinapic acid (SA) is a derivative of hydroxycinnamic acid and found in various vegetables and fruit species. Aim was to evaluate the anticancer effects of SA in PC-3 and LNCaP human prostate cancer cells. The effect of SA on cell viability was determined using XTT assay. Expressions of 8 genes for apoptosis and 6 genes for metastasis were evaluated by qPCR. Caspase-3 activity was determined using caspase-3 colorimetric assay kit. Effect of SA on cell invasion was evaluated with cell invasion assay. The IC50 dose of SA in PC-3 and LNCaP cells was found to be 1000 μM for 72 h...
May 21, 2018: Gene
https://www.readbyqxmd.com/read/29792732/phosphatidylinositol-3-kinase-%C3%AE-and-%C3%AE-isoforms-play-key-roles-in-metastasis-of-prostate-cancer-du145-cells
#2
Zhe Zhang, Jie Liu, Yingying Wang, Xiao Tan, Wennan Zhao, Xiaoxue Xing, Yuling Qiu, Ran Wang, Meihua Jin, Guanwei Fan, Ping Zhang, Yuxu Zhong, Dexin Kong
Metastasis is the main cause of the lethality of prostate cancer. Class I phosphatidylinositol 3-kinases (PI3Ks), which contain 4 isoforms, α, β, δ, and γ, are known to play important roles in cell growth, migration, invasion, and so on. However, the respective role of each PI3K isoform in cancer cell migration and invasion remains unknown. In a study that aimed to elucidate the respective role of the 4 PI3K isoforms, we investigated the change in migratory and invasive ability of DU145 cells after treatment with each PI3K isoform-specific inhibitor...
May 24, 2018: FASEB Journal: Official Publication of the Federation of American Societies for Experimental Biology
https://www.readbyqxmd.com/read/29792652/prostate-cancer-local-treatment-after-radiorecurrence-salvage-cryoablation
#3
EDITORIAL
Rodrigo Donalisio da Silva, Fernando J Kim
No abstract text is available yet for this article.
May 2018: International Braz J Urol: Official Journal of the Brazilian Society of Urology
https://www.readbyqxmd.com/read/29792651/prostate-cancer-local-treatment-after-radiorecurrence-surgery-back-to-the-future
#4
EDITORIAL
Leonardo O Reis, Paul L Nguyen
No abstract text is available yet for this article.
May 2018: International Braz J Urol: Official Journal of the Brazilian Society of Urology
https://www.readbyqxmd.com/read/29792650/prostate-cancer-local-treatment-after-radiorecurrence-hifu-high-intensity-focused-ultrasound
#5
EDITORIAL
Stenio de Cassio Zequi, Thiago Camelo Mourão, Gustavo Cardoso Guimarães
No abstract text is available yet for this article.
May 2018: International Braz J Urol: Official Journal of the Brazilian Society of Urology
https://www.readbyqxmd.com/read/29792311/pedf-regulates-plasticity-of-a-novel-lipid-mtoc-axis-in-prostate-cancer-associated-fibroblasts
#6
Francesca Nardi, Philip Fitchev, Omar E Franco, Jelena Ivanisevic, Adrian Scheibler, Simon W Hayward, Charles B Brendler, Michael A Welte, Susan E Crawford
Prostate tumors make metabolic adaptations to ensure adequate energy and amplify cell cycle regulators such as centrosomes to sustain their proliferative capacity. It is not known whether cancer associated fibroblasts (CAFs) undergo metabolic re-programming. We postulated that CAFs augment lipid storage and amplify centrosomal or non-centrosomal microtubule organizing centers (MTOCs) through a pigment epithelium-derived factor (PEDF)-dependent lipid-MTOC signaling axis. Primary normal human prostate fibroblasts (NFs) and CAFs were evaluated for lipid content, triacylglycerol-regulating proteins, MTOC number and distribution...
May 23, 2018: Journal of Cell Science
https://www.readbyqxmd.com/read/29792198/radioligand-therapy-of-metastatic-castration-resistant-prostate-cancer-current-approaches
#7
REVIEW
Zool Hilmi Awang, Markus Essler, Hojjat Ahmadzadehfar
Prostate Cancer is the forth most common type of cancer. Prostate-specific membrane antigen (PSMA) is anchored in the cell membrane of prostate epithelial cells. PSMA is highly expressed on prostate epithelial cells and strongly up-regulated in prostate cancer. Therefore it is an appropriate target for diagnostic and therapy of prostate cancer and its metastases. This article discusses several articles on radionuclide treatments in prostate cancer and the results on PSMA therapy with either beta or alpha emitters as a salvage therapy...
May 23, 2018: Radiation Oncology
https://www.readbyqxmd.com/read/29790867/fluorine-18-fluorocholine-pet-ct-parameters-predictive-for-hematological-toxicity-to-radium-223-therapy-in-castrate-resistant-prostate-cancer-patients-with-bone-metastases-a-pilot-study
#8
Lavinia Vija Racaru, Mathieu Sinigaglia, Salim Kanoun, Fayçal Ben Bouallègue, Ilan Tal, Sévérine Brillouet, Mathilde Bauriaud-Mallet, Slimane Zerdoud, Lawrence Dierickx, Delphine Vallot, Olivier Caselles, Erwan Gabiache, Pierre Pascal, Frederic Courbon
PURPOSE: This study aims to predict hematological toxicity induced by Ra therapy. We investigated the value of metabolically active bone tumor volume (MBTV) and total bone lesion activity (TLA) calculated on pretreatment fluorine-18-fluorocholine (F-FCH) PET/CT in castrate-resistant prostate cancer (CRPC) patients with bone metastases treated with Ra radionuclide therapy. PATIENTS AND METHODS: F-FCH PET/CT imaging was performed in 15 patients with CRPC before treatment with Ra...
May 21, 2018: Nuclear Medicine Communications
https://www.readbyqxmd.com/read/29790667/differences-in-cancer-survival-among-white-and-black-cancer-patients-by-presence-of-diabetes-mellitus-estimations-based-on-seer-medicare-linked-data-resource
#9
Clara Lam, Kathleen Cronin, Rachel Ballard, Angela Mariotto
Diabetes prevalence and racial health disparities in the diabetic population are increasing in the US. Population-based cancer-specific survival estimates for cancer patients with diabetes have not been assessed. The Surveillance, Epidemiology, and End Results (SEER)-Medicare linkage provided data on cancer-specific deaths and diabetes prevalence among 14 separate cohorts representing 1 068 098 cancer patients ages 66 +  years diagnosed between 2000 and 2011 in 17 SEER areas. Cancer-specific survival estimates were calculated by diabetes status adjusted by age, stage, comorbidities, and cancer treatment, and stratified by cancer site and sex with whites without diabetes as the reference group...
May 23, 2018: Cancer Medicine
https://www.readbyqxmd.com/read/29790383/focal-treatment-for-unilateral-prostate-cancer-using-hifu-a-comprehensive-study-of-pooled-data
#10
Simone Albisinni, Christian Melot, Fouad Aoun, Ksenija Limani, Alexandre Peltier, Pascal Rischmann, Roland van Velthoven
BACKGROUND: Focal therapy for prostate cancer (PCa) remains experimental. Aim of the current study is to review available evidence and perform a pooled analysis exploring oncologic and functional results of High Intensity Focal Ultrasound (HIFU) focal therapy for the treatment of unilateral PCa. METHODS: The National Library of Medicine Database was searched for relevant articles. A wide search was performed including the combination of following words: "HIFU", "prostate", "cancer", "focal"...
May 23, 2018: Journal of Endourology
https://www.readbyqxmd.com/read/29789876/-new-treatment-option-apalutamide-for-nonmetastatic-castration-resistant-prostate-cancer
#11
B Hadaschik, A Panic
No abstract text is available yet for this article.
May 22, 2018: Der Urologe. Ausg. A
https://www.readbyqxmd.com/read/29789815/challenging-case-robot-assisted-laparoscopic-prostatectomy-after-prior-suprapubic-open-prostatectomy
#12
Shirin Razdan, Sanjay Razdan
Introduction: Given the ubiquity of robot-assisted laparoscopic prostatectomy (RALP) for treatment of localized prostate cancer, more surgeons are encountering challenging cases, either secondary to difficult anatomy, prior abdominal surgery, or prior radiation therapy. Our case is of RALP in a patient after prior suprapubic prostatectomy. Case Presentation: A 61-year-old otherwise healthy Hispanic gentleman presented for consultation after being found to have Gleason 4 + 4 = 8 prostate cancer on transrectal ultrasound-guided biopsy by an outside provider in July 2017...
2018: Journal of Endourology Case Reports
https://www.readbyqxmd.com/read/29789766/salvage-high-dose-rate-brachytherapy-for-prostate-cancer-persistence-after-brachytherapy-repeated-use-of-a-polyethylene-glycol-hydrogel-spacer
#13
Rodrigo Hepp, Thilo Eggert, Georg Schabl, Lars Herberholz, Tim Petry, Razvan Galalae
Purpose: The aim of this study is to determine if a repeated hydrogel injection in a previously irradiated patient prior to salvage high-dose-rate brachytherapy (HDR-BT) is feasible. Material and methods: A 61-year-old man with an organ confined (cT1c cN0 cM0, Gleason score 3 + 3 = 6, initial prostate-specific antigen [PSA] 7.9 ng/ml) prostate cancer was previously treated with HDR-BT (3 fractions of 11.5 Gy every 2nd week) after hydrogel injection to reduce the rectal dose...
April 2018: Journal of Contemporary Brachytherapy
https://www.readbyqxmd.com/read/29789764/a-single-institution-analysis-of-low-dose-rate-brachytherapy-5-year-reported-survival-and-late-toxicity-outcomes
#14
REVIEW
Michael Chao, Sandra Spencer, Mario Guerrieri, Wei Ding, Mehran Goharian, Huong Ho, Michael Ng, Danielle Healey, Alwin Tan, Chee Cham, Daryl Lim Joon, Nathan Lawrentschuk, Douglas Travis, Shomik Sengupta, Yee Chan, Andrew Troy, Trung Pham, David Clarke, Peter Liodakis, Damien Bolton
Purpose: To report the 5-year biochemical relapse-free survival (BRFS), overall survival (OS), and long-term toxicity outcomes of patients treated with low-dose-rate (LDR) brachytherapy as monotherapy for low- to intermediate-risk prostate cancer. Material and methods: Between 2004 and 2011, 371 patients were treated with LDR brachytherapy as monotherapy. Of these, 102 patients (27%) underwent transurethral resection of the prostate (TURP) prior to implantation...
April 2018: Journal of Contemporary Brachytherapy
https://www.readbyqxmd.com/read/29789236/-study-of-the-beneficial-effects-of-triptorelin-on-lower-urinary-tract-symptoms-in-algeria-in-patients-with-non-localized-prostate-cancer
#15
K Hachi, K Boualga, K Chettibi, M Harouni, M Ounnoughene, N Bekkat-Berkani, P Maisonobe, M J Yousfi
INTRODUCTION: This study aims to assess the effectiveness of triptorelin on lower urinary tract symptoms (LUTS) in Algerian patients with non-localized prostate cancer in routine practice. MATERIALS: This prospective, observational, non-interventional, multicentre study was conducted in Algeria. Included patients who had locally advanced or metastatic prostate cancer and were treated with triptorelin 11.25mg given every 12 weeks. LUTS were evaluated with the International Prostate Symptom Score (IPSS) until week 48 after treatment initiation...
May 20, 2018: Progrès en Urologie
https://www.readbyqxmd.com/read/29789235/-pathology-findings-after-radical-prostatectomy-for-prostate-cancer-in-patients-eligible-for-active-surveillance-contribution-of-multiparametric-mri-to-treatment-decision
#16
A Martin-Malburet, G Marcq, X Leroy, P Guiffart, J-C Fantoni, V Flamand, A Villers, P Puech, A Ouzzane
OBJECTIVES: To analyze, in patients with prostate cancer (PC) potentially eligible for active surveillance (AS), whether multiparametric-MRI (mp-MRI) predicts presence of clinically significant cancer on radical prostatectomy (RP) specimen. METHODS: We identified 77 men with PC eligible for AS (PSA≤15ng/mL, stage≤T2a, Gleason score≤6, up to 3 positive cores, maximal cancer core length≤5mm) who underwent RP between 01/2008 and 08/2015. All patients had prebiopsy mp-MRI followed by systematic±targeted biopsies...
May 20, 2018: Progrès en Urologie
https://www.readbyqxmd.com/read/29788736/evaluation-of-overall-survival-rate-of-different-therapies-in-the-treatment-of-t1-t3-prostate-cancer-a-network-meta-analysis
#17
S Y Chen, Y Du, Q Shao, J S Li, H Y Chen
We performed this network meta-analysis (NMA) in order to compare the overall survival rate of six different therapies of T1-T3 prostate cancer (PC). The therapies include radiotherapy (RT), endocrine therapy (ET), Cryoablation (CRYO), radical prostatectomy (RP), RT+ET and RP+ET. Pubmed, Embase, Cochrane Library, Google Scholar, Web of Science and MEDLINE were searched to collect relevant literature from the inception of the study till February 2017. Cohort studies meeting the inclusion criteria were included in the study...
March 14, 2018: Neoplasma
https://www.readbyqxmd.com/read/29788164/what-is-the-optimal-systemic-treatment-of-men-with-metastatic-hormone-naive-prostate-cancer-a-stopcap-systematic-review-and-network-meta-analysis
#18
C L Vale, D J Fisher, I R White, J R Carpenter, S Burdett, N W Clarke, K Fizazi, G Gravis, N D James, M D Mason, M K B Parmar, L H Rydzewska, C J Sweeney, M R Spears, M R Sydes, J F Tierney
Background: Our prior Systemic Treatment Options for Cancer of the Prostate systematic reviews showed improved survival for men with metastatic hormone-naive prostate cancer when abiraterone acetate plus prednisolone/prednisone (AAP) or docetaxel (Doc), but not zoledronic acid (ZA), were added to androgen-deprivation therapy (ADT). Trial evidence also suggests a benefit of combining celecoxib (Cel) with ZA and ADT. To establish the optimal treatments, a network meta-analysis (NMA) was carried out based on aggregate data (AD) from all available studies...
May 1, 2018: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/29787892/the-role-of-bisphosphonates-or-denosumab-in-light-of-the-availability-of-new-therapies-for-prostate-cancer
#19
REVIEW
Fred Saad, Cora N Sternberg, Peter F A Mulders, Daniela Niepel, Bertrand F Tombal
Most men with advanced prostate cancer will develop bone metastases, which have a substantial impact on quality of life. Bone metastases can lead to skeletal-related events (SREs), which place a burden on patients and healthcare systems. For men with castration-resistant prostate cancer (CRPC) and bone metastases, the treatment landscape has evolved rapidly over the past few years. The relatively recent approvals of the hormonal agents abiraterone acetate and enzalutamide, second-line chemotherapy cabazitaxel, and the radiopharmaceutical radium-223 dichloride (radium-223), have provided clinicians with a greater choice of treatments...
May 3, 2018: Cancer Treatment Reviews
https://www.readbyqxmd.com/read/29787376/symptom-assessment-to-guide-treatment-selection-and-determine-progression-in-metastatic-castration-resistant-prostate-cancer-expert-opinion-and-review-of-the-evidence
#20
REVIEW
Fred Saad, Frédéric Pouliot, Brita Danielson, Charles Catton, Anil Kapoor
Multiple new agents to treat metastatic castration-resistant prostate cancer (mCRPC) have become available in recent years; however, the appropriate timing and sequencing of these agents have yet to be elucidated. Until accurate biomarkers become available to allow more focused therapeutic targeting for this population, treatment selection for men with mCRPC will continue to be driven largely by close assessment of patient-related factors and symptoms. Pain, as the predominant symptom of mCRPC, is often the focus when assessing progression and the need for a change in treatment...
May 14, 2018: Canadian Urological Association Journal, Journal de L'Association des Urologues du Canada
keyword
keyword
26059
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"